As the field of oral pathology has evolved, the nomenclature and classification of oral mucosal diseases with a remarkable risk of malignant transformation have undergone several modifications. In 2005, the World Health Organization (WHO) introduced the concept of oral potentially malignant disorders (OPMDs) as an alternative to the terms for oral precancerous lesions and precancerous conditions. In the consensus report by the WHO Collaborating Center for Oral Cancer of 2021, OPMD is defined as "any oral mucosal abnormality that is associated with a statistically increased risk of developing oral cancer."This definition encompasses a range of conditions, in-cluding oral leukoplakia, oral submucous fibrosis, proliferative verrucous leukoplakia, oral lichen planus, and other lesions. In light of the complex etiology, unclear pathogenesis, and carcinogenesis of OPMDs, early and precise diagnosis and treatment can contribute to the secondary prevention of oral cancer. For this reason, this review, which aims to provide a basis for the precise clinical diagnosis of OPMDs, was performed. Its aim was achieved by reviewing the historical evolution and research progress of the nomenclature, classification, and histopathological diagnostic criteria of OPMDs.
Humans ; Mouth Neoplasms/diagnosis* ; Precancerous Conditions/diagnosis* ; Leukoplakia, Oral/diagnosis* ; Lichen Planus, Oral/pathology* ; Oral Submucous Fibrosis/pathology* ; Mouth Mucosa/pathology* ; World Health Organization

With the rapid advancement of artificial intelligence(AI)in healthcare,clinical decision support system(CDSS)is gradually integrated into clinical workflows.While CDSS enhances diagnostic and therapeutic efficiency and accuracy,it has also sparked complex debates regarding accountability.This article systematically examines the current global landscape of accountability challenges associated with CDSS.It delves into the mechanisms underlying these challenges,focusing on 5 key dimensions:ambiguity in liability attribution,the"black-box"nature of algorithms,data bias,backward legal and regulatory systems,and heterogeneity in deployment environments.To address these issues,a collaborative governance framework centered on whole-lifecycle governance is proposed.Specifically,the framework advocates:enhancing AI trustworthiness through technical pathways;constructing innovative mechanisms such as risk-based tiered regulation and no-fault compensation funds through legal and regulatory pathways;strengthening institutional internal controls through organizational pathways;and reshaping a new professional paradigm of"human-AI collaboration"through ethical and educational pathways.The study argues that resolving CDSS accountability dilemmas is not only critical for fostering trustworthy AI in medicine but also essential for safeguarding patient safety,ensuring healthcare equity,and providing clinicians with clear liability boundaries and robust professional protections amid technological transformation.

Endogenously eliminating the hematoma is a favorable strategy in addressing intracerebral hemorrhage (ICH). This study sought to determine the role of retinoid X receptor-α (RXR-α) in the context of hematoma absorption after ICH. Our results showed that pharmacologically activating RXR-α with bexarotene significantly accelerated hematoma clearance and alleviated neurological dysfunction after ICH. RXR-α was expressed in microglia/macrophages, neurons, and astrocytes. Mechanistically, bexarotene promoted the nuclear translocation of RXR-α and PPAR-γ, as well as reducing neuroinflammation by modulating microglia/macrophage reprograming from the M1 into the M2 phenotype. Furthermore, all the beneficial effects of RXR-α in ICH were reversed by the PPAR-γ inhibitor GW9662. In conclusion, the pharmacological activation of RXR-α confers robust neuroprotection against ICH by accelerating hematoma clearance and repolarizing microglia/macrophages towards the M2 phenotype through PPAR-γ-related mechanisms. Our data support the notion that RXR-α might be a promising therapeutic target for ICH.

Endogenously eliminating the hematoma is a favorable strategy in addressing intracerebral hemorrhage (ICH). This study sought to determine the role of retinoid X receptor-α (RXR-α) in the context of hematoma absorption after ICH. Our results showed that pharmacologically activating RXR-α with bexarotene significantly accelerated hematoma clearance and alleviated neurological dysfunction after ICH. RXR-α was expressed in microglia/macrophages, neurons, and astrocytes. Mechanistically, bexarotene promoted the nuclear translocation of RXR-α and PPAR-γ, as well as reducing neuroinflammation by modulating microglia/macrophage reprograming from the M1 into the M2 phenotype. Furthermore, all the beneficial effects of RXR-α in ICH were reversed by the PPAR-γ inhibitor GW9662. In conclusion, the pharmacological activation of RXR-α confers robust neuroprotection against ICH by accelerating hematoma clearance and repolarizing microglia/macrophages towards the M2 phenotype through PPAR-γ-related mechanisms. Our data support the notion that RXR-α might be a promising therapeutic target for ICH.
Anilides/pharmacology* ; Cerebral Hemorrhage/drug therapy* ; Hematoma/drug therapy* ; Humans ; Macrophages ; Microglia ; Neuroprotection ; PPAR gamma ; Retinoid X Receptor alpha

Objective:To observe the therapeutic efficacy and prognosis of daratumumab combined with chemotherapy bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT) followed by daratumumab and lenalidomide maintenance treatment for primary plasma cell leukemia (PCL).Methods:The clinical data of a patient with primary PCL admitted to the First People's Hospital of Yunnan Province in January 2020 were retrospectively analyzed, and relevant literatures were reviewed.Results:The patient was diagnosed with primary PCL and treated with daratumumab combined with BD (bortezomib + dexamethasone) for 1 course and BCDD (bortezomib + cyclophosphamide + liposomaldoxorubicin + dexamethasone) for two courses. The patient was treated with daratumumab combined with allo-HSCT after complete remission. The donor cells were successfully implanted and the chimerism rate of donor cells was 94.36% without acute graft-versus-host disease reaction. And then the patient received intermittent maintenance therapy of daratumumab combined with low dose lenalidomide after transplantation, and the current remission period after transplantation reached 4 months.Conclusions:Daratumumab combined with chemotherapy bridging to allo-HSCT followed by daratumumab and lenalidomide may improve the prognosis of primary PCL and prolong survival time.

Objective To observe the clinical efficacy of the combined therapy of super-laser radiation and plum acupuncture on alopecia areata.Methods Altogether 178 alopecia areata patients were randomly divided into 3 groups:65 patients in the treatment group being given super-laser radiation and plum acupuncture,55 in the control group A solely with super-laser radiation and 58 in the control group B solely with plum acupuncture.The therapeutic effects of the treatment group and the control groups were compared by rank sum test.Results At the end of the 1st treating period,the cured cases,markedly effective cases,ordinary effective cases and invalid cases in control group A were 1,4,10 and 40;those numbers of control group B were 1,3,11 and 43;those numbers of the treatment group were 3,12,14 and 36.At the end of the 2nd treating period,those numbers of control group A were 8,8,16 and 23;those numbers of control group B were 7,8,18 and 25;those numbers of the treatment group were 11,20,19 and 15.At the end of the 3rd treating period,those numbers of A control group were 21,11,12 and 11;those numbers of B control group were 20,14,11 and 13;those numbers of the treatment group were 33,17,10 and 5.Comparing the performance of each groups at the end of the 3 periods,we found that effects were always better in the treatment group than the other two control groups.The difference between the treatment group and the other two control groups was statistically significant (P＜0.05).Conclusions It is effective and safe to use super laser radiation combined plum acupuncture on alopecia areata.The clinical efficacy of this joint method is better than either of the two separate ways.